Yesterday and today two new anti-epileptic drugs were announced. They are both generic versions of UCB, Inc.'s Keppra XR®. Keppra XR® is indicated for adjunctive therapy to treat partial onset seizures in patients with epilepsy who are 16 years of age and older.

Watson Pharmaceuticals, Inc. announced yesterday that its subsidiary, Watson Laboratories, Inc. has launched Levetiracetam extended-release 500 mg and 750 mg tablets, following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson began shipping the product yesterday.

Pharmaceutical company, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (LPI) has been granted final approval by the U.S. Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market Levetiracetam 500 mg and 750 mg extended-release tablets that are the AB-rated generic equivalent of Keppra XR®. Commercial shipment of the product has commenced.

For information regarding medications as a treatment for epilepsy, please visit our Medications page: http://epilepsyfoundation.org/aboutepilepsy/treatment/medications/index.cfm.
For more information on Watson, visit their website www.watson.com and for more information on Lupin, visit their website www.lupinworld.com.


« Back To All News

© 2021 Epilepsy Foundation Connecticut